<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02659397</url>
  </required_header>
  <id_info>
    <org_study_id>1002-035</org_study_id>
    <nct_id>NCT02659397</nct_id>
  </id_info>
  <brief_title>A Study Of Pharmacokinetics, Pharmacodynamics And Safety Of Adding ETC-1002 To Atorvastatin 80 mg</brief_title>
  <official_title>A Study to Assess the Pharmacokinetics, Pharmacodynamics and Safety of Adding ETC-1002 180 mg to Atorvastatin 80 mg Background Therapy in Statin-Treated Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Esperion Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Esperion Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to measure the amount of atorvastatin and ETC-1002 in
      the blood, to determine how ETC-1002 affects the level of LDL-cholesterol (bad cholesterol)
      and other markers of health and disease in blood and urine, and to see how ETC-1002 is
      tolerated in the body compared to placebo when added to stable atorvastatin 80 mg background
      therapy in statin-treated patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak plasma concentration (Cmax) pharmacokinetics of atorvastatin and its active metabolites</measure>
    <time_frame>2 weeks</time_frame>
    <description>Fold change in Cmax from prior-to to following 2 week treatment with ETC-1002</description>
  </primary_outcome>
  <primary_outcome>
    <measure>24-hour area under the curve (AUC) pharmacokinetics of atorvastatin and its active metabolites</measure>
    <time_frame>2 weeks</time_frame>
    <description>Fold change in AUC from prior-to to following 2 week treatment with ETC-1002</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent change in LDL-cholesterol</measure>
    <time_frame>4 weeks</time_frame>
    <description>Percent Change from baseline to 4 week treatment, incremental lowering of LDL-C</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent change in hsCRP</measure>
    <time_frame>4 weeks</time_frame>
    <description>Percent change from baseline to following 4 week treatment with ETC-1002</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in total cholesterol</measure>
    <time_frame>4 weeks</time_frame>
    <description>Percent change from baseline to following 4 week treatment with ETC-1002</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in non-HDL-cholesterol</measure>
    <time_frame>4 weeks</time_frame>
    <description>Percent change from baseline to following 4 week treatment with ETC-1002</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in apolipoprotein B</measure>
    <time_frame>4 weeks</time_frame>
    <description>Percent change from baseline to following 4 week treatment with ETC-1002</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24-hour post dose plasma concentration pharmacokinetics of ETC-1002 and its active metabolite</measure>
    <time_frame>2 weeks</time_frame>
    <description>Fold change in trough exposure from prior-to to following 2 week treatment with ETC-1002</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">68</enrollment>
  <condition>Hyperlipidemia</condition>
  <arm_group>
    <arm_group_label>ETC-1002 + Atorvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ETC-1002 180 mg treatment, oral once daily added-on to Atorvastatin 80 mg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + Atorvastatin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo treatment, oral once daily added-on to Atorvastatin 80 mg once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ETC-1002</intervention_name>
    <description>Blinded ETC-1002 180 mg tablet once daily for 4 weeks (Weeks 1 to 4)</description>
    <arm_group_label>ETC-1002 + Atorvastatin</arm_group_label>
    <other_name>bempedoic acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>Atorvastatin 80 mg tablet once daily for 8 weeks (Weeks -4 to 4)</description>
    <arm_group_label>ETC-1002 + Atorvastatin</arm_group_label>
    <arm_group_label>Placebo + Atorvastatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Blinded ETC-1002-matched placebo tablet once daily for 4 weeks (Weeks 1 to 4)</description>
    <arm_group_label>Placebo + Atorvastatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Taking daily stable statin doses for at least 4 weeks prior to screening visit.

          -  LDL-C between 100-220 mg/dL for patients taking daily high-intensity statin (for 4
             weeks prior to switching to sponsor -provided atorvastatin 80 mg/day and stopping all
             other lipid-regulating drugs and supplements) at the screening visit; or,

          -  LDL-C between 115-220 mg/dL for patients taking moderate- or low-intensity statin (for
             4 weeks prior to switching to sponsor -provided atorvastatin 80 mg/day and stopping
             all other lipid-regulating drugs and supplements) at the screening visit.

          -  Must be willing to discontinue other lipid-regulating therapies during the study

        Exclusion Criteria:

          -  History of acute significant cardiovascular disease.

          -  Current clinically significant cardiovascular disease.

          -  History of inability to tolerate any statin at any dose due to muscle-related pain or
             weakness.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mary McGowan, MD</last_name>
    <role>Study Director</role>
    <affiliation>Esperion Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Northridge</city>
        <state>California</state>
        <zip>91324</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33765</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33126</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Port Orange</city>
        <state>Florida</state>
        <zip>32127</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62711</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <state>New Jersey</state>
        <zip>08009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>57701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Carrollton</city>
        <state>Texas</state>
        <zip>75006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>West Jordan</city>
        <state>Utah</state>
        <zip>84088</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Arlington</city>
        <state>Virginia</state>
        <zip>22203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lynchburg</city>
        <state>Virginia</state>
        <zip>24501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Renton</city>
        <state>Washington</state>
        <zip>98057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Thompson PD, Rubino J, Janik MJ, MacDougall DE, McBride SJ, Margulies JR, Newton RS. Use of ETC-1002 to treat hypercholesterolemia in patients with statin intolerance. J Clin Lipidol. 2015 May-Jun;9(3):295-304. doi: 10.1016/j.jacl.2015.03.003. Epub 2015 Mar 19.</citation>
    <PMID>26073387</PMID>
  </reference>
  <reference>
    <citation>Nikolic D, Mikhailidis DP, Davidson MH, Rizzo M, Banach M. ETC-1002: a future option for lipid disorders? Atherosclerosis. 2014 Dec;237(2):705-10. doi: 10.1016/j.atherosclerosis.2014.10.099. Epub 2014 Oct 31. Review.</citation>
    <PMID>25463109</PMID>
  </reference>
  <reference>
    <citation>Filippov S, Pinkosky SL, Newton RS. LDL-cholesterol reduction in patients with hypercholesterolemia by modulation of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase. Curr Opin Lipidol. 2014 Aug;25(4):309-15. doi: 10.1097/MOL.0000000000000091. Review.</citation>
    <PMID>24978142</PMID>
  </reference>
  <reference>
    <citation>Gutierrez MJ, Rosenberg NL, Macdougall DE, Hanselman JC, Margulies JR, Strange P, Milad MA, McBride SJ, Newton RS. Efficacy and safety of ETC-1002, a novel investigational low-density lipoprotein-cholesterol-lowering therapy for the treatment of patients with hypercholesterolemia and type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol. 2014 Mar;34(3):676-83. doi: 10.1161/ATVBAHA.113.302677. Epub 2014 Jan 2.</citation>
    <PMID>24385236</PMID>
  </reference>
  <reference>
    <citation>Ballantyne CM, Davidson MH, Macdougall DE, Bays HE, Dicarlo LA, Rosenberg NL, Margulies J, Newton RS. Efficacy and safety of a novel dual modulator of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase in patients with hypercholesterolemia: results of a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial. J Am Coll Cardiol. 2013 Sep 24;62(13):1154-62. doi: 10.1016/j.jacc.2013.05.050. Epub 2013 Jun 13.</citation>
    <PMID>23770179</PMID>
  </reference>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 12, 2016</study_first_submitted>
  <study_first_submitted_qc>January 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 20, 2016</study_first_posted>
  <disposition_first_submitted>December 14, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>December 20, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">December 21, 2016</disposition_first_posted>
  <last_update_submitted>December 20, 2016</last_update_submitted>
  <last_update_submitted_qc>December 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>LDL-cholesterol</keyword>
  <keyword>Hypercholesterolemia</keyword>
  <keyword>ETC-1002</keyword>
  <keyword>Adenosine triphosphate citrate lyase</keyword>
  <keyword>Atorvastatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

